Further investigations are warranted to unravel the precise molecular mechanisms by which IGF2BP2 influences autophagy and to explore its potential as a therapeutic target in glioma treatment, as our study revealed that knockdown of IGF2BP2 can sensitize TMZ to advance the autophagy of cancer cells. This evidence concerns the gene IGF2BP2 and central nervous system cancer.